RNAC PE Ratio & Valuation, Is RNAC Overvalued

Historical Valuation

Cartesian Therapeutics Inc (RNAC) is now in the Fair zone, suggesting that its current forward PS ratio of 369.92 is considered Fairly compared with the five-year average of -5.55. The fair price of Cartesian Therapeutics Inc (RNAC) is between 2.12 to 7.61 according to relative valuation method.

Relative Value

Fair Zone

2.12-7.61

Current Price：5.88

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cartesian Therapeutics Inc (RNAC) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cartesian Therapeutics Inc (RNAC) has a current Price-to-Book (P/B) ratio of -4.90. Compared to its 3-year average P/B ratio of 78.73, the current P/B ratio is approximately -106.23% higher. Relative to its 5-year average P/B ratio of 78.73, the current P/B ratio is about -106.23% higher. Cartesian Therapeutics Inc (RNAC) has a Forward Free Cash Flow (FCF) yield of approximately -39.19%. Compared to its 3-year average FCF yield of -20.41%, the current FCF yield is approximately 92.07% lower. Relative to its 5-year average FCF yield of -20.41%, the current FCF yield is about 92.07% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for RNAC competitors is 72.75, providing a benchmark for relative valuation. Cartesian Therapeutics Inc Corp (RNAC.O) exhibits a P/S ratio of 369.92, which is 408.47% above the industry average. Given its robust revenue growth of 1129.87%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of RNAC increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of RNAC in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is RNAC currently overvalued or undervalued?

What is Cartesian Therapeutics Inc (RNAC) fair value?

RNAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cartesian Therapeutics Inc (RNAC) is between 2.12 to 7.61 according to relative valuation method.

How does RNAC's valuation metrics compare to the industry average?

The average P/S ratio for RNAC's competitors is 72.75, providing a benchmark for relative valuation. Cartesian Therapeutics Inc Corp (RNAC) exhibits a P/S ratio of 369.92, which is 408.47% above the industry average. Given its robust revenue growth of 1129.87%, this premium appears sustainable.

What is the current P/B ratio for Cartesian Therapeutics Inc (RNAC) as of Mar 31 2026?

As of Mar 31 2026, Cartesian Therapeutics Inc (RNAC) has a P/B ratio of -4.90. This indicates that the market values RNAC at -4.90 times its book value.

What is the current FCF Yield for Cartesian Therapeutics Inc (RNAC) as of Mar 31 2026?

As of Mar 31 2026, Cartesian Therapeutics Inc (RNAC) has a FCF Yield of -39.19%. This means that for every dollar of Cartesian Therapeutics Inc's market capitalization, the company generates -39.19 cents in free cash flow.

What is the current Forward P/E ratio for Cartesian Therapeutics Inc (RNAC) as of Mar 31 2026?

As of Mar 31 2026, Cartesian Therapeutics Inc (RNAC) has a Forward P/E ratio of -1.99. This means the market is willing to pay $-1.99 for every dollar of Cartesian Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cartesian Therapeutics Inc (RNAC) as of Mar 31 2026?

As of Mar 31 2026, Cartesian Therapeutics Inc (RNAC) has a Forward P/S ratio of 369.92. This means the market is valuing RNAC at $369.92 for every dollar of expected revenue over the next 12 months.

RNAC Valuation